Published in the Journal of Attention Disorders in 2007, researchers Mark Sciutto and Miriam Eisenberg set out to evaluate the evidence both for and against the overdiagnosis of ADHD. They reviewed recent prevalence studies and research on factors that affect diagnostic accuracy.

For ADHD to be genuinely overdiagnosed, the number of false positives (children wrongly diagnosed with ADHD) would need to substantially exceed the number of false negatives (children who actually have ADHD but are missed). The review found no evidence that false positives systematically outweigh false negatives.

The authors concluded that there is not sufficient justification for the widely held belief that ADHD is overdiagnosed. They noted that while individual cases of misdiagnosis certainly exist, the pattern across the research does not support a systemic problem of overdiagnosis.

Published in Pediatrics in 2015 (with the meta-regression data from 2014), a team led by Guilherme Polanczyk analyzed 175 eligible research reports published across three decades to determine whether the true prevalence of ADHD among children has been increasing over time.

The pooled worldwide prevalence estimate was 7.2%, ranging from 6.7% to 7.8%. Critically, the year a study was conducted was not associated with higher or lower prevalence estimates. In other words, the actual rate of ADHD in child populations has remained stable over decades.

This finding is important because if ADHD were being overdiagnosed due to loosening criteria or cultural pressure, you would expect to see prevalence estimates climbing over time. Instead, the data shows the underlying rate is steady. The authors concluded that rising diagnosis rates in clinical practice most likely reflect improved awareness and better access to care, not a true increase in the condition or overdiagnosis.

Published in Pediatrics in 2013, researchers used the nationally representative Early Childhood Longitudinal Study (17,100 children from the kindergarten class of 1998-1999) and tracked them through eighth grade.

By eighth grade, African American children were 69% less likely and Latino children 50% less likely than white children to receive an ADHD diagnosis. Children of other racial/ethnic backgrounds were 46% less likely. Among those who were diagnosed, minority children were also less likely to be taking prescription medication for the condition.

Importantly, neither Black nor Hispanic children displayed less frequent ADHD-related behaviors according to kindergarten teacher reports. The disparity in diagnosis was not explained by differences in family income, parental education, or the severity of behavioral symptoms. This pattern strongly suggests the real problem is underdiagnosis in minority communities rather than overdiagnosis in white communities.

Published in Pediatrics in 2016, this longitudinal study tracked children from fifth through tenth grade to compare symptom rates with actual diagnosis rates across racial and ethnic groups.

In fifth grade, 12% of African American children showed symptoms suggestive of ADHD compared to 7% of white children. By tenth grade, the gap widened further: 13% of Black children had suggestive symptoms versus 9% of white children. Despite showing more symptoms, Black children were diagnosed at roughly half the rate of white children - only 10% received a diagnosis by tenth grade compared to 19% of white children.

Treatment disparities were even more striking among children with the most severe symptoms. By tenth grade, 65% of white patients with severe ADHD were taking stimulant medication, compared to just 36% of Black and 30% of Latino patients.

Published in the Journal of Attention Disorders in 2023, researchers Darby Attoe and Emma Climie conducted a systematic review of eight studies examining the impact of undiagnosed ADHD in adult women.

The most striking finding involves the diagnostic ratio: in childhood, boys are diagnosed with ADHD about three times as often as girls (3:1 ratio). By adulthood, the ratio evens out to roughly 1:1. This shift strongly suggests that girls are being systematically missed during childhood, only catching up with diagnoses as adults. On average, girls receive an ADHD diagnosis five years later than boys - at age 12 versus age 7.

Women with ADHD were rated as more impaired on every measure of symptoms and scored higher on scales for anxiety and depression compared to men. About 14% of girls with ADHD were prescribed antidepressants before ever being evaluated or treated for ADHD, compared to only 5% of boys. This pattern shows that many girls and women are being treated for secondary conditions while the underlying ADHD goes unrecognized.

Published in Neuroscience and Biobehavioral Reviews in 2021, the World Federation of ADHD brought together 87 leading researchers and clinicians from around the world to produce an updated International Consensus Statement.

The authors generated 208 empirically supported conclusions about ADHD, drawing only from studies with more than 2,000 participants or meta-analyses with at least five studies. This strict methodology ensured only the most robust findings were included. The consensus confirmed that ADHD is a well-validated neurodevelopmental disorder with strong genetic, neurobiological, and epidemiological support.

The experts specifically addressed the overdiagnosis narrative, noting that misconceptions about ADHD stigmatize affected people, reduce the credibility of healthcare providers, and prevent or delay treatment. They emphasized that the weight of scientific evidence supports ADHD as a real condition that remains underrecognized in many populations, particularly girls, adults, and racial minorities.

Published in the CDC''s Morbidity and Mortality Weekly Report in October 2024, this analysis used data from the National Center for Health Statistics Rapid Surveys System, collected during October and November 2023, covering a nationally representative sample of U.S. adults.

An estimated 15.5 million American adults (6.0% of the adult population) reported having a current ADHD diagnosis. The most revealing finding was that approximately half of these adults received their ADHD diagnosis only at age 18 or older. This means millions of people lived through their entire childhood and teenage years with unrecognized ADHD, suggesting widespread underdiagnosis rather than overdiagnosis.

Among adults with ADHD who were taking stimulant medication, 71.5% reported difficulty getting their prescriptions filled because the medication was unavailable at pharmacies. This shortage of access to treatment further undermines the overdiagnosis narrative - if ADHD were being overdiagnosed, you would expect abundant treatment supply, not shortages.

Published in the Journal of the American Academy of Child and Adolescent Psychiatry in 2012, researchers led by Jalpa Doshi conducted a systematic review of 19 U.S.-based studies published between 1990 and 2011 that measured the economic costs of ADHD in children, adolescents, adults, and their families.

The total annual economic burden of ADHD in the United States was estimated at $143 billion to $266 billion. Adults accounted for the majority of costs at $105 billion to $194 billion, while children and adolescents accounted for $38 billion to $72 billion. Spillover costs borne by family members added another $33 billion to $43 billion.

For adults, the largest cost category was productivity and income losses at $87 billion to $138 billion, driven by unemployment, reduced workplace performance, and missed workdays. A separate analysis found that undiagnosed adults with ADHD symptoms had worse depression, lower quality of life, and lower work productivity than those with diagnosed and treated ADHD. These enormous hidden costs suggest the real public health problem is underdiagnosis and undertreatment, not overdiagnosis.

Published in the Journal of Global Health in 2021, researchers conducted a systematic review and meta-analysis of 40 studies from 21 countries examining the prevalence of ADHD in adults. The analysis specifically distinguished between "symptomatic" prevalence (people who meet diagnostic criteria on validated questionnaires) and "diagnosed" prevalence (people who have received a formal clinical diagnosis).

The pooled symptomatic prevalence of adult ADHD was 6.76% based on self-report screening scales. When restricted to studies using clinical diagnostic criteria, the pooled prevalence was 2.58%. The gap between these two numbers - roughly 4 percentage points - represents millions of adults worldwide who meet the clinical threshold for ADHD but have never been formally diagnosed or treated.

This diagnostic gap was particularly wide in low- and middle-income countries, where mental health services are less accessible. Even in high-income countries, the gap remained substantial. The finding that the majority of adults who meet ADHD criteria remain undiagnosed directly contradicts the overdiagnosis narrative and points to underdiagnosis as the more pressing global problem.